Table 3

Survival to discharge home, treatments and morbidities of those receiving intensive care

1991–1992199720052016–2017*
n=332n=190n=229n=250
N (%)Adj OR (95% CI), p value†N (%)Adj OR (95% CI),
p value†
N (%)Adj OR (95% CI),
p value†
N (%)
Survival to discharge home227 (68.4)0.24 (0.15 to 0.38), p<0.001152 (80.0)0.61 (0.35 to 1.06), p=0.08170 (74.2)0.41 (0.25 to 0.68), p=0.001217 (86.8)
Surfactant151 (45.5)0.19 (0.12 to 0.28), p<0.001162 (85.3)1.21 (0.72 to 2.03), p=0.47205 (89.5)1.94 (1.13 to 3.34), p=0.02202/247 (81.8)
IVH 3 or 446 (13.9)1.53 (0.89 to 2.62), p=0.1219 (10.0)0.97 (0.51 to1.87), p=0.9435 (15.3)1.59 (0.89 to 2.83), p=0.1127/249 (10.8)
cPVL21 (6.3)5.47 (1.62 to 18.5), p=0.0111 (5.8)5.09 (1.35 to 19.1), p=0.026 (2.6)2.22 (0.54 to 9.15), p=0.273 (1.2)
NEC30/331 (9.1)0.56 (0.33 to 0.95), p=0.0312 (6.3)0.35 (0.17 to 0.71), p=0.00332 (14.0)0.91 (0.54 to 1.53), p=0.7137 (14.8)
ROP received treatment‡13/331 (3.9)0.45 (0.21 to 0.97), p=0.0411/187 (5.9)0.49 (0.21 to 1.11), p=0.0910/219 (4.6)0.38 (0.16 to 0.89), p=0.0325/249 (10.0)
BPD (Oxygen at 36 weeks)§116/237 (48.9)1.21 (0.80 to 1.81), p=0.3768/153 (44.4)0.76 (0.47 to 1.23), p=0.26106/182 (58.2)1.65 (1.07 to 2.52), p=0.02108/220 (49.1)
Survival to discharge home free of major morbidities¶99 (29.8)0.58 (0.39 to 0.86), p=0.0173 (38.4)1.11 (0.71 to 1.76), p=0.6462 (27.1)0.58 (0.38 to 0.89), p=0.0194 (37.6)
Postnatal corticosteroids108 (32.5)1.17 (0.81 to 1.71), p=0.4081 (42.6)1.48 (0.96 to 2.28), p=0.0855 (24.0)0.63 (0.41 to 0.98), p=0.0477 (30.8)
Surgery77 (23.2)0.94 (0.63 to 1.39), p=0.7453 (27.9)1.06 (0.68 to 1.67), p=0.7970 (30.6)1.32 (0.86 to 2.01), p=0.2062 (24.8)
  • *2016–2017 cohort as a reference for all comparisons.

  • †Adjusted for inborn status (ie, birth in a tertiary perinatal centre), gestation at birth, sex, birth weight z-score.

  • ‡Laser or cryotherapy (1991–1992, 1997 and 2005); Bevacizumab injections and/or laser therapy (2016–2017).

  • §Denominator—alive at 36 weeks postmenstrual age.

  • ¶Major morbidities include IVH 3 or 4, cPVL, NEC, ROP received treatment and/or bronchopulmonary dysplasia.

  • BPD, bronchopulmonary dysplasia; cPVL, cystic periventricular leukomalacia; IVH 3 or 4, intraventricular haemorrhage grade 3 or 4; NEC, necrotising enterocolitis Bell stage 2 or worse; ROP, retinopathy of prematurity.